Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245769 | 1.00 | CPS1 (0.52) | CPS1MTORKDM4EALDH1A1HTT | |
| SCHEMBL22172219 | 0.85 | CPS1 (0.48) | CPS1MTORKDM4EALDH1A1HTT | |
| SCHEMBL4936365 | 0.84 | RAD52 (0.54) | KDM4EALDH1A1HTTHRH4 | |
| SCHEMBL7878481 | 0.84 | ALDH1A1 (0.55) | CPS1MTORKDM4EALDH1A1HTT | |
| SCHEMBL3396511 | 0.84 | CPS1 (0.56) | CPS1MTORKDM4ELMNAHRH4 | |
| SCHEMBL30309461 | 0.84 | CPS1 (0.56) | CPS1MTORKDM4ELMNAHRH4 | |
| SCHEMBL22172181 | 0.84 | PIK3CA (0.49) | CPS1MTORKDM4EALDH1A1HTT | |
| SCHEMBL22164004 | 0.83 | HRH4 (0.43) | KDM4EALDH1A1LMNAHRH4 | |
| SCHEMBL4935992 | 0.83 | ALDH1A1 (0.49) | MTORALDH1A1LMNAHRH4 | |
| SCHEMBL30309520 | 0.83 | ALDH1A1 (0.49) | MTORALDH1A1LMNAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377907-B | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CPS1 2277/4885MTOR 94/4885KDM4E 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.